以组蛋白去乙酰化酶为靶点的抗肿瘤研究  

Research on histone deacetylase as a target for anti-cancer therapy

作　　者：李楠[1] 蒋大明[2] 刘双萍[3] 

机构地区：[1]延边大学医学院病理学教研室,延吉133002 [2]吉林省松原市人民医院外科 [3]延边大学肿瘤研究所,延吉133002

出　　处：《国际肿瘤学杂志》2016年第2期116-118,共3页Journal of International Oncology

基　　金：国家自然科学基金，吉林省科技发展项目(20130522010JH) National Natural Science Foundation of China，Science and Technology Develop Project of Jilin

摘　　要：细胞核内组蛋白乙酰化与去乙酰化失衡可诱发肿瘤.组蛋白去乙酰化酶（HDAC）作用于组蛋白,使其去乙酰化,维系组蛋白乙酰化与去乙酰化的平衡状态,与癌相关基因转录表达、细胞增殖分化及细胞凋亡等过程密切相关.HDAC抑制剂目前是国内外研究的热点,已有十多种HDAC抑制剂用于治疗血液肿瘤和恶性实体瘤,表现出明显的抗肿瘤活性.The disequilibrium of histone acetylation and deacetylation may cause tumor.Histone deacetylases （HDACs） maintain the equilibrium between histone acetylation and deacetylation by catalyzing the deacetylation of histone.They are related to many regulation processes containing transcription of oncogene,cell proliferation and differentiation,apoptosis and so on.HDACs inhibitors have become the hot field of researches,more than ten different HDACs inhibitors are testing for the treatment of both hematological and solid malignancies and show obvious anti-tumor activity.

关 键 词：肿瘤 组蛋白去乙酰化酶 组蛋白去乙酰化酶抑制剂 

分 类 号：R96[医药卫生—药理学]